- * Body weight ≥40.0 kg and ≤100 kg at screening
- * Documented diagnosis of beta-thalassemia or Hb E/beta-thalassemia
- * Red blood cell (RBC) transfusion dependence, defined as at least 6 RBC units in the 24 weeks prior to randomization and no transfusion-free period for ≥35 days during that period
- * Ability to understand the requirements of the study and provide written informed consent
Beta-Thalassemia
Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia
NCT04938635 | PHASE 2 | INTERVENTIONAL
The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Investigator site #
Whittier,California,United States,90603
Investigational site #
Plovdiv,California,Bulgaria,90603-2137
Investigational site #
Sofia,California,Bulgaria,90603-2137
Investigational site #
Stara Zagora,California,Bulgaria,90603-2137
Investigator Site
Jerusalem,California,Israel,90603-2137
Investigator Site
Petah tikva,California,Israel,90603-2137
Investigator Site
Safed,California,Israel,90603-2137
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov